Literature DB >> 15135702

Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients.

Evelyn Regar1, Pedro A Lemos, Francesco Saia, Muzaffer Degertekin, Kengo Tanabe, Chi-Hang Lee, Chourmouzios A Arampatzis, Angela Hoye, Georgios Sianos, Pim de Feyter, Willem J van der Giessen, Peter C Smits, Ron T van Domburg, Patrick W Serruys.   

Abstract

Sirolimus-eluting stents have been used in our institution for all percutaneous interventions, without clinical or anatomic exclusion criteria, as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital registry. We analyzed the incidence of (sub)acute stent thrombosis after sirolimus-eluting stent implantation in an unselected population of 510 consecutive patients. At 3-month follow-up, (sub)acute stent thrombosis was diagnosed in 2 patients (0.4%) 6 hours and 11 days after the procedure, respectively. These cases occurred in diabetic women with complex coronary lesions. Intravascular ultrasound examination showed inadequate stent expansion and uncovered distal dissection as possible mechanical explanations for the thrombosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135702     DOI: 10.1016/j.amjcard.2004.02.013

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Very late thrombosis after implantation of sirolimus eluting stent.

Authors:  E Karvouni; S Korovesis; D G Katritsis
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

2.  Late adverse events after drug-eluting stent implantation.

Authors:  David F Kong; Eric L Eisenstein; Robert Harrington
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

3.  Recurrent very late thrombosis of drug-eluting stent: Optical coherence tomography findings.

Authors:  Nobuaki Kobayashi; Masamichi Takano; Noritake Hata; Masanori Yamamoto; Takuro Shinada; Yasuhiro Takahashi; Kazunori Tomita; Mitsunobu Kitamura; Osamu Kurihara; Kyoichi Mizuno
Journal:  J Cardiol Cases       Date:  2010-08-10

Review 4.  The risk of drug-eluting stent thrombosis with noncardiac surgery.

Authors:  Emmanouil S Brilakis; Subhash Banerjee; Peter B Berger
Journal:  Curr Cardiol Rep       Date:  2007-09       Impact factor: 2.931

5.  Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.

Authors:  Suresh R Mulukutla; Oscar C Marroquin; Helen A Vlachos; Faith Selzer; Catalin Toma; Kevin E Kip; J Dawn Abbott; Elizabeth Holper; Joon S Lee; Sameer Khandhar; Michael Kutcher; Sheryl Kelsey; Conrad Smith; David Faxon; David O Williams
Journal:  Am J Cardiol       Date:  2012-12-01       Impact factor: 2.778

6.  Two-year outcome of Turkish patients treated with Zotarolimus versus Paclitaxel eluting stents in an unselected population with coronary artery disease in the real world: a prospective non-randomized registry in southern Turkey.

Authors:  Davran Ciçek; Hasan Pekdemir; Cevahir Haberal; Nihat Kalay; Süleyman Binici; Hakan Altay; Haldun Müderrisoğlu
Journal:  Int J Med Sci       Date:  2011-01-08       Impact factor: 3.738

7.  Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience.

Authors:  Antonios Karanasos; Nicolas Van Mieghem; Nienke van Ditzhuijzen; Cordula Felix; Joost Daemen; Anouchska Autar; Yoshinobu Onuma; Mie Kurata; Roberto Diletti; Marco Valgimigli; Floris Kauer; Heleen van Beusekom; Peter de Jaegere; Felix Zijlstra; Robert-Jan van Geuns; Evelyn Regar
Journal:  Circ Cardiovasc Interv       Date:  2015-05       Impact factor: 6.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.